ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: Evidence from a peripheral model

Barbara Borroni, Francesca Colciaghi, Lucia Pastorino, Silvana Archetti, Paola Corsini, Flaminio Cattabeni, Monica Di Luca, Alessandro Padovani

Research output: Contribution to journalArticle

Abstract

Three major amyloid precursor protein (APP) forms with apparent molecular weight ranging from 106 to 130 kDa are present in human platelets. Alzheimer disease (AD) is associated with a decreased APP forms ratio (APPr) between the three major forms. A total of 25 mild to moderate AD patients were investigated. Platelet APPr was studied before and after 30 days of acetylcholinesterase-inhibitor treatment (donepezil, 5 mg daily). Patients were grouped into non-ε4 carriers and ε4 carriers according to apolipoprotein E (ApoE) genotype. At baseline, all patients showed low APPr levels and no significant difference was found between the two ApoE subgroups. After treatment, although a marked improvement in APPr was observed in most patients, non-ε4 carriers displayed a higher increase compared to ε4 carriers (P

Original languageEnglish
Pages (from-to)195-200
Number of pages6
JournalEuropean Neuropsychopharmacology
Volume12
Issue number3
DOIs
Publication statusPublished - 2002

Keywords

  • Alzheimer disease
  • Amyloid precursor protein (APP)
  • Apolipoprotein E
  • Donepezil

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Neurology
  • Pharmacology
  • Psychology(all)

Fingerprint Dive into the research topics of 'ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: Evidence from a peripheral model'. Together they form a unique fingerprint.

  • Cite this

    Borroni, B., Colciaghi, F., Pastorino, L., Archetti, S., Corsini, P., Cattabeni, F., Di Luca, M., & Padovani, A. (2002). ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: Evidence from a peripheral model. European Neuropsychopharmacology, 12(3), 195-200. https://doi.org/10.1016/S0924-977X(02)00013-5